How do EXELIXIS, INC. and Metallus Inc. compare by revenue?

EXELIXIS, INC. reported revenue of $598.7M in Q4 FY2025, while Metallus Inc. reported $308.3M in Q1 FY2026. EXELIXIS, INC. is 1.9× larger by last-quarter revenue.

Which is growing revenue faster, EXELIXIS, INC. or Metallus Inc.?

EXELIXIS, INC.'s latest revenue grew 5.6% year-over-year, versus 9.9% for Metallus Inc.. Metallus Inc. is growing faster on a YoY basis.

Which has a higher gross margin, EXELIXIS, INC. or Metallus Inc.?

EXELIXIS, INC.'s gross margin is 95.6% vs Metallus Inc.'s 8.1%. EXELIXIS, INC. converts more of each revenue dollar into gross profit.

Which has a higher net margin, EXELIXIS, INC. or Metallus Inc.?

EXELIXIS, INC.'s net margin is 40.8% vs Metallus Inc.'s 1.8%. EXELIXIS, INC. has the higher bottom-line margin.

What is the 2-year revenue CAGR for EXELIXIS, INC. vs Metallus Inc.?

Over the trailing 8 quarters, EXELIXIS, INC. compounded revenue at roughly 18.7% per year, versus 2.3% for Metallus Inc.. EXELIXIS, INC. has the faster medium-term growth trajectory.

Where does this EXEL vs MTUS data come from?

All figures are parsed directly from SEC EDGAR 10-Q / 10-K / 20-F / 6-K filings (for US-listed issuers) or EDINET filings (for Japanese issuers), then normalised into a common schema. Numbers update automatically as new filings are released.

vs

Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Metallus Inc. (MTUS). Click either name above to swap in a different company.

EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $308.3M, roughly 1.9× Metallus Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs 1.8%, a 39.1% gap on every dollar of revenue. On growth, Metallus Inc. posted the faster year-over-year revenue change (9.9% vs 5.6%). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 2.3%).

EXELIXIS, INC.EXELEarnings & Financial Report

Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Metallus Inc.MTUSEarnings & Financial Report

NYSE · Materials · Steel Works, Blast Furnaces & Rolling Mills (Coke Ovens)

EXEL vs MTUS — Head-to-Head

Bigger by revenue

EXEL

1.9× larger

$598.7M

$308.3M

Growing faster (revenue YoY)

MTUS

+4.3% gap

9.9%

5.6%

Higher net margin

EXEL

39.1% more per $

40.8%

1.8%

Faster 2-yr revenue CAGR

EXEL

Annualised

18.7%

2.3%

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric	EXEL	MTUS
Revenue	$598.7M	$308.3M
Net Profit	$244.5M	$5.4M
Gross Margin	95.6%	8.1%
Operating Margin	39.3%	—
Net Margin	40.8%	1.8%
Revenue YoY	5.6%	9.9%
Net Profit YoY	74.8%	315.4%
EPS (diluted)	$0.89	$0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue

EXEL

MTUS

Q1 26	$598.7M	$308.3M
Q4 25	$597.8M	$267.3M
Q3 25	$568.3M	$305.9M
Q2 25	$555.4M	$304.6M
Q1 25	$566.8M	$280.5M
Q4 24	—	$240.5M
Q3 24	$539.5M	$227.2M
Q2 24	$637.2M	$294.7M

Net Profit

EXEL

MTUS

Q1 26	$244.5M	$5.4M
Q4 25	$193.6M	$-14.3M
Q3 25	$184.8M	$8.1M
Q2 25	$159.6M	$3.7M
Q1 25	$139.9M	$1.3M
Q4 24	—	$-21.4M
Q3 24	$118.0M	$-5.9M
Q2 24	$226.1M	$4.6M

Gross Margin

EXEL

MTUS

Q1 26	95.6%	8.1%
Q4 25	96.9%	2.2%
Q3 25	96.6%	11.4%
Q2 25	96.5%	10.6%
Q1 25	96.5%	7.8%
Q4 24	—	4.5%
Q3 24	96.8%	5.3%
Q2 24	97.2%	8.2%

Operating Margin

EXEL

MTUS

Q1 26	39.3%	—
Q4 25	39.6%	-7.7%
Q3 25	37.6%	3.6%
Q2 25	33.6%	2.8%
Q1 25	28.8%	1.0%
Q4 24	—	-10.1%
Q3 24	25.2%	-3.1%
Q2 24	43.3%	2.1%

Net Margin

EXEL

MTUS

Q1 26	40.8%	1.8%
Q4 25	32.4%	-5.3%
Q3 25	32.5%	2.6%
Q2 25	28.7%	1.2%
Q1 25	24.7%	0.5%
Q4 24	—	-8.9%
Q3 24	21.9%	-2.6%
Q2 24	35.5%	1.6%

EPS (diluted)

EXEL

MTUS

Q1 26	$0.89	$0.13
Q4 25	$0.69	$-0.34
Q3 25	$0.65	$0.19
Q2 25	$0.55	$0.09
Q1 25	$0.47	$0.03
Q4 24	—	$-0.46
Q3 24	$0.40	$-0.13
Q2 24	$0.77	$0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric	EXEL	MTUS
Cash + ST InvestmentsLiquidity on hand	$1.1B	$104.0M
Total DebtLower is stronger	—	—
Stockholders' EquityBook value	$2.2B	$683.0M
Total Assets	$2.8B	$1.1B
Debt / EquityLower = less leverage	—	—

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments

EXEL

MTUS

Q1 26	$1.1B	$104.0M
Q4 25	$988.5M	$156.7M
Q3 25	$791.1M	$191.5M
Q2 25	$1.0B	$190.8M
Q1 25	$1.1B	$180.3M
Q4 24	—	$240.7M
Q3 24	$1.2B	$254.6M
Q2 24	$1.0B	$272.8M

Total Debt

EXEL

MTUS

Q1 26	—	—
Q4 25	—	—
Q3 25	—	$0
Q2 25	—	$0
Q1 25	—	$5.4M
Q4 24	—	$5.4M
Q3 24	—	$13.2M
Q2 24	—	$13.2M

Stockholders' Equity

EXEL

MTUS

Q1 26	$2.2B	$683.0M
Q4 25	$2.2B	$686.0M
Q3 25	$2.0B	$697.7M
Q2 25	$2.1B	$690.0M
Q1 25	$2.2B	$686.1M
Q4 24	—	$690.5M
Q3 24	$2.3B	$712.7M
Q2 24	$2.1B	$736.3M

Total Assets

EXEL

MTUS

Q1 26	$2.8B	$1.1B
Q4 25	$2.8B	$1.1B
Q3 25	$2.7B	$1.2B
Q2 25	$2.8B	$1.1B
Q1 25	$2.9B	$1.1B
Q4 24	—	$1.1B
Q3 24	$3.0B	$1.1B
Q2 24	$2.8B	$1.1B

Debt / Equity

EXEL

MTUS

Q1 26	—	—
Q4 25	—	—
Q3 25	—	0.00×
Q2 25	—	0.00×
Q1 25	—	0.01×
Q4 24	—	0.01×
Q3 24	—	0.02×
Q2 24	—	0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric	EXEL	MTUS
Operating Cash FlowLast quarter	$333.5M	—
Free Cash FlowOCF − Capex	$332.4M	—
FCF MarginFCF / Revenue	55.5%	—
Capex IntensityCapex / Revenue	0.2%	0.0%
Cash ConversionOCF / Net Profit	1.36×	—
TTM Free Cash FlowTrailing 4 quarters	$875.8M	—